CIK 0001133416 · Non-accelerated filer<br>Smaller reporting company
GALECTIN THERAPEUTICS INC
Sign in to watch- Ticker
- GALT
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- NV
- Entity type
- operating
- EIN
- 043562325
- Phone
- 678-620-3186
- Business address
- 4960 PEACHTREE INDUSTRIAL BOULEVARD, SUITE 240, NORCROSS, GA, 30071
- Former names
- PRO PHARMACEUTICALS INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-11-13 | Jamil Khurram Chief Medical Officer | Sale 10b5-1 | −21,867 | $5.47 | $120K | 4,479 |
| 2025-11-13 | Jamil Khurram Chief Medical Officer | Option exercise 10b5-1 | +41,500 | $2.20 | $91K | 45,979 |
| 2025-11-13 | Jamil Khurram Chief Medical Officer | Sale 10b5-1 | −41,500 | $5.47 | $227K | 4,479 |
| 2025-11-13 | Jamil Khurram Chief Medical Officer | Option exercise 10b5-1 | +41,500 | $2.50 | $104K | 45,979 |
| 2025-11-13 | Jamil Khurram Chief Medical Officer | Sale 10b5-1 | −41,500 | $5.47 | $227K | 4,479 |
| 2025-11-13 | Jamil Khurram Chief Medical Officer | Option exercise 10b5-1 | +16,250 | $1.23 | $20K | 20,729 |
| 2025-11-13 | Jamil Khurram Chief Medical Officer | Sale 10b5-1 | −16,250 | $5.47 | $89K | 4,479 |
| 2025-11-13 | Jamil Khurram Chief Medical Officer | Option exercise · Stock option (right to buy) 10b5-1 | −41,500 | 108,500 | ||
| 2025-11-13 | Jamil Khurram Chief Medical Officer | Option exercise · Stock option (right to buy) 10b5-1 | −41,500 | 58,500 | ||
| 2025-11-13 | Jamil Khurram Chief Medical Officer | Option exercise · Stock option (right to buy) 10b5-1 | −16,250 | 48,750 | ||
| 2025-11-11 | 10X Fund, L.P. 10% owner | Sale | −40,000 | $5.25 | $210K | 5,832,207 |
| 2025-11-10 | LEWIS JOEL President and CEO | Option exercise 10b5-1 | +1,867 | $2.39 | $4K | 834,459 |
| 2025-11-10 | LEWIS JOEL President and CEO | Sale 10b5-1 | −1,867 | $6.03 | $11K | 832,592 |
| 2025-11-10 | CALLICUTT JACK W Chief Financial Officer | Option exercise 10b5-1 | +1,880 | $1.98 | $4K | 9,694 |
| 2025-11-10 | CALLICUTT JACK W Chief Financial Officer | Sale 10b5-1 | −1,880 | $6.02 | $11K | 7,614 |
| 2025-11-10 | CALLICUTT JACK W Chief Financial Officer | Option exercise 10b5-1 | +1,675 | $1.11 | $2K | 9,289 |
| 2025-11-10 | CALLICUTT JACK W Chief Financial Officer | Sale 10b5-1 | −1,675 | $6.03 | $10K | 7,614 |
| 2025-11-10 | CALLICUTT JACK W Chief Financial Officer | Option exercise 10b5-1 | +1,736 | $1.23 | $2K | 9,350 |
| 2025-11-10 | CALLICUTT JACK W Chief Financial Officer | Sale 10b5-1 | −1,736 | $6.03 | $10K | 7,614 |
| 2025-11-10 | CALLICUTT JACK W Chief Financial Officer | Option exercise · Stock option (right to buy) 10b5-1 | −1,880 | 37,706 |
Page 8 of 15 · 291 trades